To date, Plexxikon has signed major collaborations with Roche, Servier, Wyeth and Genentech, and the company has received over $170 million in non-dilutive funding from these partnerships.

Roche (2008) – Polycystic Kidney Disease
Status: Active
Focus: Co-development and commercialization of PLX5568, and other selective Raf inhibitors

Roche (2006) – Oncology
Status: Active
Focus: Co-development and commercialization of PLX4032, and other selective Raf inhibitors

Servier (2006) – Cardiovascular
Status: Completed
Focus: Discovery of non-peptidic renin inhibitors

Wyeth (2004) – Type 2 Diabetes and other metabolic disease
Status: Completed
Focus: Co-development of PPM-204 (PLX204), and other diabetes and obesity compounds

Genentech (2003) – Oncology
Status: Completed
Focus: Discovery of drug leads for single undisclosed kinase target